Non-small cell lung cancer
Not recruitingStudy of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure
Study of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure
- Disease:Non-small cell lung cancer
- Substances:AmivantamabCarboplatin+3
Spain- Participants:18–64 years · 65+ years
- Substances:Amivantamab
- Sponsor:Janssen Cilag International










